ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0613

The Subsets of Synovial Fluid Derived Fibroblasts in Clinical Features of Rheumatoid Arthritis

Kuninobu Wakabayashi1, Takeo Isozaki2, Kunika Shimizu1, Kazutaka Kawamori1, Noriko Konishi1, Shinichiro Nishimi1, Sho Ishii1, Shin Ohta3 and Tsuyoshi Kasama1, 1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Japan, 2Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, 3Division of Respiratory Medicine and Allergology, Department of Medicine, Showa University School of Medicine, Shinagawa-ku, Japan

Meeting: ACR Convergence 2022

Keywords: Fibroblasts, Synovial, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Etiology and Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Synovial fibroblasts in rheumatoid arthritis (RA) secrete inflammatory cytokines and chemokines, invade and degrade cartilage, and make pannus formation. Synovial fibroblasts characterized by the expression podoplanin (PDPN) are composed three functionally distinct subsets, CD34–THY1–, CD34–THY1+, and CD34+THY1+ population. It is reported that the phenotypical and functional characterization of synovial fluid (SF) derived fibroblast do not deviate from synovial tissue fibroblast. The objective of this study is to investigate phenotypic characterization of SF derived fibroblast and the difference of subsets proportion in clinical features of RA.

Methods: We consecutively collected the SF samples aspirated from knee joint of RA patients at the new-onset or at the flare. The SFs were centrifuged and the cell pellets were resuspended in medium. The attached cells were cultured until 80% confluent growth was observed, and cells were harvested and passaged. Flow cytometry was performed by triple staining with PDPN, CD34 and THY1. The data are expressed as median (25-75 percentile).

Results: We got the SFs from 37 patients with RA. At the primary culture, CD34–THY1+ and CD34–THY1– were major subsets [36.1% (9.5-66.0) and 61.6% (24.0-84.6), respectively] in PDPN+ fibroblasts [11.2% (5.2-23.2)]. The proportion of CD34–THY1+ subsets in new-onset group (n=25) was higher those in flare group (n=12) [58.7% (16.4-79.2) and 13.8% (8.8-33.5), respectively, p< 0.001]. The proportion of CD34–THY1– subsets in flare group was higher those in new-onset group [78.3% (62.8-86.4) and 39.1% (7.8-78.2), respectively, p< 0.001]. Furthermore, the proportion of CD34–THY1+ subsets in seronegative RA (n=18) was higher than those in seropositive RA (n=19) [58.7% (23.0-80.5) and 18.9% (7.5-43.0), respectively, p< 0.05]. By passaging from P0 to P2 (n=22), the proportion of PDPN+ fibroblasts was increased. The proportions of CD34+THY1+ and CD34–THY1+ subsets were also increased, while the proportion of CD34–THY1– was decreased. Comparing these differences between the new-onset group (n=13) and the flare group (n=9), the proportion of PDPN+ fibroblasts in the new-onset group was increased with a statistically significant difference. In addition, the proportions of CD34+THY1+ and CD34–THY1+ subsets in the flare group were statistically significantly increased.

Conclusion: These data show that the major subset proportion of SF-derived fibroblasts is different between at the new-onset and at the flare, or seropositive and seronegative. Moreover, the subset of CD34–THY1+ and CD34+THY1+ have proliferative phenotype. The difference of SF-derived fibroblast subsets proportion may be involved in clinical features in RA.


Disclosures: K. Wakabayashi, None; T. Isozaki, None; K. Shimizu, None; K. Kawamori, None; N. Konishi, None; S. Nishimi, None; S. Ishii, None; S. Ohta, None; T. Kasama, None.

To cite this abstract in AMA style:

Wakabayashi K, Isozaki T, Shimizu K, Kawamori K, Konishi N, Nishimi S, Ishii S, Ohta S, Kasama T. The Subsets of Synovial Fluid Derived Fibroblasts in Clinical Features of Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/the-subsets-of-synovial-fluid-derived-fibroblasts-in-clinical-features-of-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-subsets-of-synovial-fluid-derived-fibroblasts-in-clinical-features-of-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology